Prostate cancer - Discussions

ENG

BRCAaway

ASCO GU 2024

BRCAAway - practice changing or hypothesis generating…

G. Morgan, A. Bjartell, S. Chowdhury, E. Efstathiou

ENG

EMBARK

ASCO GU 2024

Combination vs. monotherapy - a great new option for…

O. Grimm, N. Shore, A. Bjartell, S. Chowdhury, E. Efstathiou

ENG

GETUG-AFU 18

ASCO GU 2024

Is "more" always better?

O. Grimm, A. Bjartell, G. Morgan, S. Chowdhury, E. Efstathiou

ENG

CONTACT-2

ASCO GU 2024

Cabo + IO: Interesting but not practice changing?!

A. Merseburger, G. Morgan, A Bjartell, Y. Loriot, S. Chowdhury, E. Efstathiou

Prostate cancer - 100 sec

ENG

ASCO GU 2024

Cognitive function in ART treatment

Anders Bjartell, MD, PhD

ENG

BCRAAway

ASCO GU 2024

Combination NHT + PARP makes sense

Axel S. Merseburger, MD

ASCO GU 2024

Therapy Intensification Still Neglected in mHSPC

Peter Goebell, MD

ENG

ASCO GU 2024

Gleason 3+3 - cancer or not?

Anders Bjartell, MD

ENG

ASCO GU 2024

Salvage radiation with anti-androgen superior to…

Tarik Esen, MD

ENG

CONTACT-2

ASCO GU 2024

First positive study of IO therapy in mCRPC

Axel S. Merseburger, MD

ENG

BCRAAway

ASCO GU 2024

Further testing before olaparib combination

Peter Goebell, MD

ENG

SEPTA

ASCO GU 2024

Stockholm3 validated in multiethnic cohort

Tarik Esen, MD

ENG

EMBARK, Prostate Cancer General Session

ASCO GU 2024

Dose de-escalation in different ways

Anders Bjartell, Md, PhD

ENG

BRCAAway, CONTACT-02

ASCO GU 2024

Insights and news for mCRPC

Philipp Ivanyi, MD

ENG

BCRAAway

ASCO GU 2024

Evaluating the recombination-repair mutations in…

Eleni Efstathiou, MD, PhD

ENG

GETUG-AFU 18

ASCO GU 2024

Long-term dose escalation - Therapy in high-risk…

Peter J. Goebell, MD

ENG

FORMULA-509

ASCO GU 2024

Quality of life under intensive therapy

Peter Goebell, MD

ENG

BRCAaway

ASCO GU 2024

Olaparib + Arbiraterone better compared to either alone

Tarik Esen, MD

ENG

CONTACT-2

ASCO GU 2024

Still a difficult time for androgenic inhibitors in…

Yohann Loriot, MD, PhD

ENG

EMBARK, GETUG-AFU

ASCO GU 2024

Localized PCa - news for radiotherapy and biochemical…

Philipp Ivanyi, MD

ENG

CONTACT-2

ASCO GU 2024

Combination of cabozantinib & checkpoint inhibitor

Anders Bjartell, MD, PhD

ENG

BRCAaway

ASCO GU 2024

BRCAaway - PARP combination study

Anders Bjartell, MD, PhD

ENG

GETUG-AFU 18

ASCO GU 2024

Higher radiation is effective in high-risk PCA

Axel S. Merseburger, MD

ENG

CONTACT-2

ASCO GU 2024

What about the clinical benefit?

Eleni Efstathiou, MD, PhD

ENG

ASCO GU 2024

Relugolix combined with androgen signaling in real word…

Eleni Efstathiou, MD, PhD

ENG

EMBARK

ASCO GU 2024

Enzalutamide therapy as option for biochemical…

Axel S. Merseburger, MD

Prostate cancer - multilanguage

GRE

CONTACT-2, BCRAAway

ASCO GU 2024

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Eleni Efstathiou, MD, PhD

TUR

BRCAaway

ASCO GU 2024

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Tarik Esen, MD

TUR

Prostate Cancer General Session

ASCO GU 2024

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Tarik Esen, MD

TUR

SEPTA

ASCO GU 2024

SEPTA calismasi: Stockholm3 un multietnik hasta…

Tarik Esen, MD

SWE

ASCO GU 2024

Gleason 3+3 ska vi kalla de cancer eller inte?

Anders Bjartell, MD, PhD

FRA

CONTACT-2

ASCO GU 2024

Une période encore difficile pour les inhibiteurs…

Yohann Loriot, MD, PhD

SWE

CONTACT-2

ASCO GU 2024

Kombination av cabozantinib och immunterapi

Anders Bjartell, MD, PhD

TUR

ASCO GU 2024

Post-RP salvage radyoterapi hormonoterapi ile konbine…

Tarik Esen, MD

SWE

ACE

ASCO GU 2024

Kognitiv påverkan av abirateron och enzalutamid?

Anders Bjartell, MD, PhD

SWE

BRCAaway

ASCO GU 2024

BRCAAway - PARP hämmare, abiraterone eller i…

Anders Bjartell, MD, PhD

Urothelial cancer - Discussions

ENG

EV-302

ASCO GU 2024

New standard of care, but still open questions!

O. Grimm, J. Bellmunt, B. Rini, P. Grivas, T. Powles

ENG

COXEN

ASCO GU 2024

The emerging field of biomarkers in bladder cancer

V. Grünwald, J.Bellmunt, Y. Loriot, P. Grivas

ENG

TROPHY-U-01

ASCO GU 2024

ADC + ICI: new data for platinum-refractory bladder…

V. Grünwald, P. Grivas, B. Rini, Y. Loriot

ENG

AMBASSADOR, CHECKMATE-274

ASCO GU 2024

Advances in (neo)-adjuvant treatment in urothelial…

V. Grünwald, J. Bellmunt, B. Rini, P. Grivas, T. Powles

Urothelial cancer - 100 sec

ENG

UNITE

ASCO GU 2024

EV as standard in 3rd line mUC

Axel S. Merseburger, MD

ENG

EV-302

ASCO GU 2024

Update on EV-302

Joaquim Bellmunt, MD, PhD

ENG

CheckMate 274

ASCO GU 2024

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Gil Morgan, MD

ENG

Ambassador, CheckMate 274

ASCO GU 2024

Perioperative adjuvant therapy in urothelial cancer

Joaquim Bellmunt, MD, PhD

ENG

EV-302

ASCO GU 2024

EV + Pembro new first-line standard in localized…

Axel S. Merseburger, MD

ENG

Ambassador

ASCO GU 2024

Adjuvant therapy in urothelial carcinoma : is the…

Ignacio Durán, MD

ENG

Ambassador, CheckMate 274

ASCO GU 2024

Another success for an ICI?

Yohann Loriot, MD, PhD

ENG

ABACUS

ASCO GU 2024

Biomarker update

Simon Chowdhury, PhD

ENG

AMBASSADOR, CheckMate-274

ASCO GU 2024

MIBC: adjuvant PD1 - all set?!

Philipp Ivanyi, MD

ENG

ABACUS Ambassador EV-302

ASCO GU 2024

ASCO GU24 - Highlights in Bladder cancer

Petros Grivas, MD, PhD

ENG

AMBASSADOR

ASCO GU 2024

Pembrolizumab adjuvant in bladder cancer

Axel S. Merseburger, MD

ENG

ASCO GU 2024

HER2 and bladder cancer

Simon Chowdhury, PhD

ENG

EV-302

ASCO GU 2024

Should we start forgetting the Galsky Criteria in…

Ignacio Duran, MD, PhD

Ambassador, EV-302, ABACUS

ASCO GU 2024

Highlights in bladder cancer at ASCO GU24

Brian Rini, MD, Tom Powles, MD

ENG

EV-302

ASCO GU 2024

Update M1 urothelial cancer

Philipp Ivanyi, MD

Urothelial cancer - multilanguage

GRE

ABACUS, Ambassador, EV-302, KEYNOTE-564, LITESPARK-005

ASCO GU 2024

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Petros Grivas, Md, PhD

ESP

EV-302

ASCO GU 2024

¿Deberíamos empezar a olvidarnos de los Criterios de…

Ignacio Durán, MD, PhD

ESP

Ambassador, CheckMate 274

ASCO GU 2024

Terapia adyuvante perioperatoria en el cáncer de vejiga

Joaquim Bellmunt, MD, PhD

ESP

EV-302

ASCO GU 2024

Novedades sobre EV-302

Joaquim Bellmunt, MD, PhD

FRA

Ambassador, CheckMate 274

ASCO GU 2024

Encore un succès pour une ICI ?

Yohann Loriot, MD, PhD

ESP

Ambassador

ASCO GU 2024

Tratamiento adyuvante en cancer urotelial: ¿está…

Ignacio Durán, MD, PhD

Renal cell carcinoma - Discussions

ENG

CheckMate 9ER, CheckMate 214, CLEAR

ASCO GU 2024

Trial updates at ASCO GU24: Are the follow-up data…

P. Goebell, H. Hammers, M. Pal, T. Powles

ENG

CheckMate 67T

ASCO GU 2024

Subcutaneous vs. intravenous application: ready for…

P. Goebell, H. Hammers, S. Chowdhury, M. Pal, T. Powles

ENG

KEYNOTE-564, CheckMate 914

ASCO GU 2024

Adjuvant therapy in kidney cancer: Is immunotherapy the…

L. Krabbe, J. Bellmunt, H. Hammers, S. Chowdhury, T. Powles, M. Pal, V. Grünwald

ENG

Litespark-005

ASCO GU 2024

No surprise with the QoL data

V. Grünwald, H. Hammers, S. Chowdhury, B. Rini, M. Pal, T. Powles

Renal cell carcinoma - 100 sec

ENG

LBA359

ASCO GU 2024

Overall survival benefit - Pembro after surgery

Axel S. Merseburger, MD

ENG

CheckMate-9ER, CheckMate-214, Clear

ASCO GU 2024

Long-term follow-up of first-line trials

Philipp Ivanyi, MD

ENG

Keynote-564, CheckMate 914, CheckMate 67T, Litespark-005, CheckMate 214, CLEAR

ASCO GU 2024

Highlights in kidney cancer at ASCO GU24

Brina Rini, MD Tom Powles, MD

ENG

CABATEN

ASCO GU 2024

Cabozantinib Plus Atezolizumab in Adrenocortical…

Gil Morgan, MD

ENG

CheckMate 214

ASCO GU 2024

Durable effects of Ipi-Nivo

Viktor Grünwald, MD

ENG

Litespark-005

ASCO GU 2024

Belzutifan: Updates on QoL

Simon Chowdhury, PhD

ENG

CheckMate-67T

ASCO GU 2024

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Gil Morgan, MD

ENG

CheckMate-9ER

ASCO GU 2024

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Gil Morgan, MD

ENG

Check Mate 914, KEYNOTE-564

ASCO GU 2024

Practice changing adjuvant therapy?!

Philipp Ivanyi, MD

ENG

KEYNOTE-564

ASCO GU 2024

Perioperative treatment in renal cell carcinoma - did…

Ignacio Durán, MD, PhD

ENG

Litespark-005

ASCO GU 2024

Better QoL with Belzutifan

Viktor Grünwald, MD

ENG

KEYNOTE-564 LITESPARK-005

ASCO GU 2024

ASCO GU24 - Highlights in renal cell carcinoma

Petros Grivas, MD, PhD

ENG

CheckMate 214

ASCO GU 2024

Long-Term Data on NIVO+IPI in aRCC

Marc-Oliver Grimm, MD

ENG

CheckMate 914

ASCO GU 2024

Long-term outcome

Viktor Grünwald, MD

ENG

CLEAR

ASCO GU 2024

Tumorburden and outcome

Viktor Grünwald, MD

Renal cell carcinoma - multilanguage

ESP

KEYNOTE-564

ASCO GU 2024

Tratamiento perioperatorio en cancer renal: ¿Hemos…

Ignacio Durán, MD, PhD

GRE

ABACUS, Ambassador, EV-302, KEYNOTE-564, LITESPARK-005

ASCO GU 2024

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Petros Grivas, Md, PhD